Streetbeat News

Stock Prices

ENVB

Enveric Biosciences (NASDAQ:ENVB) has expanded its mental health-focused pipeline with a library of preclinical compounds sourced using its Psybrary platform and PsyAI system. The discovery includes compounds across seven molecule classes, offering at least 57 unique product opportunities, all protected by Enveric's intellectual property. These compounds, targeting various mental health disorders, represent potential out-licensing opportunities and non-dilutive revenue streams for Enveric. The company's stock closed at $0.87 on Tuesday.

Portfolio Pulse from Vandana Singh

February 21, 2024 | 1:01 pm

RIO

Rio Tinto PLC (NYSE:RIO) shares fell in premarket trading after reporting a 3% decline in sales revenue to $54.0 billion for FY23, slightly beating consensus but with a 12% decrease in underlying EPS to $7.25, missing expectations. Production increased in Pilbara iron ore and aluminium, but underlying EBITDA and operating cash flow declined due to lower aluminium pricing. The company announced a major renewable power purchase agreement in Australia and expects a production uplift and significant capital investment in the coming years.

Portfolio Pulse from Lekha Gupta

February 21, 2024 | 12:52 pm

AEHR

Aehr announced receiving $23M in new follow-on orders to address the increasing demand for wafer level test and burn-in of silicon carbide semiconductor devices. This development highlights the company's growing role in the semiconductor industry and its ability to meet rising market demands.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:43 pm

ALIT

Alight (NYSE:ALIT) reported Q4 adjusted EPS of $0.30, surpassing the $0.26 estimate, marking a 42.86% year-over-year increase. However, its Q4 sales of $960M fell short of the $1.03B estimate, a 1.91% increase from the previous year.

Portfolio Pulse from saritha@benzinga.com

February 21, 2024 | 12:42 pm

KZIA

Kazia Therapeutics' stock price increased following the announcement of the early conclusion of its Phase 1 Paxalisib trial in solid tumors, having reached its primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:42 pm

KHC

Kraft Heinz reiterates its 2024 financial outlook, expecting organic net sales growth of 0%-2%, adjusted operating income growth of 2%-4%, and adjusted EPS of $3.01-$3.07, aligning with a $3.03 estimate. The company anticipates positive price contributions and volume increases in the second half, with a modest expansion in adjusted gross profit margin. Challenges include a potential $45 million impact from foreign currency and debt refinancing.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:41 pm

PHIN

Phinia reported a significant decrease in its Q4 adjusted EPS to $0.71 from $1.75 YoY, despite a slight increase in sales to $882.00M from $851.00M YoY.

Portfolio Pulse from mahesh@benzinga.com

February 21, 2024 | 12:37 pm

BFH

Bread Financial has announced the approval of a new $30 million share repurchase program, signaling confidence in the company's financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:36 pm

KEYS

Keysight Technologies Inc. (NYSE:KEYS) shares fell in premarket trading on Wednesday despite reporting Q1 2024 earnings and revenues that beat analyst expectations. The decline is attributed to year-over-year revenue drops in its Communications Solutions Group and Electronic Industrial Solutions Group, along with decreased cash flow from operations and free cash flow. The company's Q2 revenue and non-GAAP EPS forecasts also fell short of estimates.

Portfolio Pulse from Nabaparna Bhattacharya

February 21, 2024 | 12:34 pm

THTX

Theratechnologies (NASDAQ:THTX) reported Q4 earnings with losses of $(0.08) per share, surpassing the $(0.24) estimate, and sales of $23.45M, slightly above the $23.36M estimate. This represents an improvement over the previous year's performance.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:33 pm